The fight against type 1 diabetes just gained a major ally.
In a move that signals fresh momentum for the cause, the T1D Fund—a Boston-based impact investment fund known for backing transformative ideas in diabetes care—has tapped Daniel McNamara to take on a pivotal new role.
He’s stepping in as the Head of Strategy and Industry Engagement, and his track record suggests big things are ahead.
Who Is Daniel McNamara?
If there’s one thing McNamara knows, it’s how to think big and get results.
With more than 15 years of experience shaping corporate strategy and managing high-stakes operations, he’s no stranger to driving innovation in complex industries.
Before joining the T1D Fund, he held a senior role at pharmaceutical giant Bristol Myers Squibb.
There, he served as Vice President of Enterprise Governance and Strategy and Business Development Operations—where he played a leading role in closing over $100 billion in mergers and acquisitions.
Beyond the numbers, McNamara was instrumental in refining how BMS executed its biggest deals.
He made sure different departments worked together smoothly, prioritized the most promising projects, and ensured that capital was deployed wisely.
That experience will now fuel his next chapter—helping move the needle in type 1 diabetes care.
What McNamara Will Be Doing at the T1D Fund
In his new position, McNamara isn’t just steering strategy—he’s also the bridge between the T1D Fund and the broader healthcare and investment communities.
He’ll be the go-to person for connecting the dots between cutting-edge research, industry partnerships, academic collaborations, and even financial analysts on Wall Street.
His mission is to spotlight promising innovations, identify where scientific breakthroughs are bubbling up, and position the Fund as the nerve center for type 1 diabetes innovation.
The Bigger Picture: What the T1D Fund Aims to Achieve
Under the leadership of CEO Elizabeth Mily, the T1D Fund continues to push forward with its bold vision: accelerating the development of treatments, preventive strategies, and eventually a cure for type 1 diabetes.
What sets this fund apart is its collaborative approach—it doesn’t go it alone.
Instead, it works closely with venture capital firms, pharmaceutical companies, and philanthropic foundations to fill in the gaps where early-stage diabetes projects often stall.
The goal is clear: create a thriving ecosystem where good ideas get the support they need to grow, reach the market, and ultimately transform lives.
What’s Coming Next?
With McNamara now on board, the T1D Fund is poised to strengthen its role as a catalyst in the type 1 diabetes space.
Expect more partnerships, deeper engagement with the investment community, and a more strategic focus on breakthrough science.
It’s a new chapter—not just for McNamara, but for everyone impacted by type 1 diabetes.
Let’s see what this new era of leadership brings.